Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
12.08. | Lilly-backed scheme aims to help UK improve obesity care | ||
12.08. | Novartis two for two as ianalumab scores again | ||
12.08. | Bayer buys into KRAS with $1.3bn Kumquat deal | ||
12.08. | Apple partners with FuturHealth on weight loss | ||
12.08. | IO Bio plans cancer vaccine filing despite trial miss | ||
11.08. | FDA starts swift review of GSK antibiotic for gonorrhoea | ||
11.08. | MorphoSys takeover delivers phase 3 win for Novartis | ||
11.08. | FDA restricts use of bluebird's Skysona gene therapy | ||
11.08. | Boehringer back in cancer with Hernexeos approval | ||
11.08. | Vinay Prasad returns to FDA | ||
08.08. | Iovance cuts staff on slower cell therapy sales growth | ||
08.08. | GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech | ||
08.08. | Click, Boehringer DTx for schizophrenia passes phase 3 test | ||
07.08. | Strand raises $153m for RNA meds, and other bio financings | ||
07.08. | FDA makes it easier to set up US manufacturing sites | ||
07.08. | England poised to roll out drug for rare eye disease LHON | ||
07.08. | Lilly weakens on oral weight-loss drug data | ||
07.08. | Pushback against Kennedy's mRNA decision builds | ||
07.08. | Jazz gets FDA okay for Chimerix brain cancer drug | ||
07.08. | Rumour mill says Novartis may want to buy Avidity | ||
06.08. | Bayer's job cull nears 12,000, with more to come | ||
06.08. | Meta harvested health data to target ads, jury concludes | ||
06.08. | Novo Nordisk weakens again on interim results readout | ||
06.08. | New medicines review process under NHS 10-year plan emerges | ||
06.08. | RFK Jr cancels $500m in funding for mRNA vaccines |